An effective vaccine is essential for controlling the spread of the SARS-CoV-2 virus. Here, we describe an influenza virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid receptor. The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture. A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (~1:200). Furthermore, ΔNA(RBD)-Flu itself causes no apparent disease in mice. It might be possible to produce a vaccine similar to ΔNA(RBD)-Flu at scale by leveraging existing platforms for the production of influenza vaccines.
【저자키워드】 SARS-CoV-2, spike, Influenza, RBD, intranasal, Live attenuated vaccine, 【초록키워드】 Vaccine, Mutation, SAR-CoV-2, Human, Influenza virus, virus, genetics, Receptor binding domain, Spread, mice, Cell culture, receptor, natural infection, disease, platform, influenza vaccines, sialic acid, coding sequence, Serum neutralizing antibody, effective, resulting, elicit, comparable, cause, reduce, the SARS-CoV-2, the SARS-CoV-2 virus, 【제목키워드】 the SARS-CoV-2,